About Verily
Verily is a data platform and technology company purpose-built to power AI for precision health. The company is uniquely positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level. Verily offers several key solutions: Pre, an AI-native platform for precision health that enables researchers to harmonize, exchange, govern, and analyze biomedical data; Lightpath, which provides personalized care to help members manage their health; Viewpoint, a solution suite to accelerate clinical research; and Sightline, solutions to monitor and mitigate population-level disease. The company recently launched Verily Me, a consumer health app that provides patients with personalized health recommendations from licensed clinicians. Verily serves customers across government agencies, health systems, life sciences companies, and individual researchers. The company has established significant partnerships with organizations including NIH, CDC, NVIDIA, Samsung, UCHealth, and the University of Colorado Anschutz. Verily operates as an independent company backed by Alphabet and other strategic investors, with a mission to make healthcare more predictive, preventive, and precise through advanced AI and data analytics.
Mission & Story
Mission
Bringing the promise of precision health to everyone, every day.
Founding Story
Verily started its next chapter as an independent company in March 2026, as announced by CEO Stephen Gillett. The company was previously part of Alphabet.
Clinical Focus
Medical conditions and clinical areas addressed by Verily.
Who It Serves
Milestones & Awards
Recent Milestones
March 2026: Announced $300M funding round led by Series X Capital; became independent company from Alphabet; launched Verily Me consumer app at SXSW 2026; announced Samsung Galaxy Watch collaboration at HIMSS26. February 2026: Launched free tier of Pre Exchange and Workbench; achieved Awardable status in DoW Tradewinds Marketplace. October 2025: Launched Verily Pre platform, Verily Me app at HLTH USA 2025, and Lifelong Health Study; announced NVIDIA collaboration and UCHealth strategic partnership. December 2025: Secured $9.2M NIH award extension. May 2026: Announced wastewater monitoring for 2026 world soccer games.
Awards & Recognition
Achieved 'Awardable' status in Department of War's Tradewinds Solutions Marketplace; selected by CDC for multi-year national wastewater monitoring collaboration
Key Partnerships
Social & Media
Latest Updates
This achievement builds on Verily’s long-standing work with the federal government, and will streamline procurement for agencies seeking to use Verily Pre
5mo ago
Verily in ‘25 and beyond: powering AI for precision health
Advancing care delivery in a rapidly changing landscape
What population data could do for the individual — early warning signs with proactive monitoring
Precision health blog
Company Details
- Headquarters
- Dallas, TX, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.